Compounds > idb 1031

Page last updated: 2024-12-07

idb 1031

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

IdB 1031: RN given refers to (+-)-isomers; RN for cpd without isomeric designation not avail 5/91; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	125309
CHEMBL ID	1224646
SCHEMBL ID	1201687
MeSH ID	M0187487

Synonyms (14)

Synonym
CHEMBL1224646
MEGXP0_000359
LMPK12140413
cyrtominetin
95272-99-4
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6,8-dimethyl-2,3-dihydrochromen-4-one
einecs 305-910-4
idb 1031
4h-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-6,8-dimethyl-, (+-)-
3-hydroxyfarrerol
(1)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-6,8-dimethyl-4-benzopyrone
SCHEMBL1201687
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6,8-dimethyl-2,3-dihydro-4h-1-benzopyran-4-one
DTXSID80915042

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay ID	Title	Year	Journal	Article
AID736055	Inhibition of deoxycholate-induced Staphylococcus aureus alpha-hemolysin F39A mutant oligomerization at 16 ug/ml by SDS-PAGE analysis	2013	European journal of medicinal chemistry, Apr, Volume: 62	Molecular insight into the inhibition mechanism of cyrtominetin to α-hemolysin by molecular dynamics simulation.
AID736058	Binding affinity to Staphylococcus aureus alpha-hemolysin F39A mutant by fluorescence quenching method	2013	European journal of medicinal chemistry, Apr, Volume: 62	Molecular insight into the inhibition mechanism of cyrtominetin to α-hemolysin by molecular dynamics simulation.
AID736063	Inhibition of alpha-hemolysin protein expression in Staphylococcus aureus 8325-4 at 4 to 256 ug/ml by Western blot analysis	2013	European journal of medicinal chemistry, Apr, Volume: 62	Molecular insight into the inhibition mechanism of cyrtominetin to α-hemolysin by molecular dynamics simulation.
AID736062	Antimicrobial activity against Staphylococcus aureus at 1024 ug/ml by broth microdilution method	2013	European journal of medicinal chemistry, Apr, Volume: 62	Molecular insight into the inhibition mechanism of cyrtominetin to α-hemolysin by molecular dynamics simulation.
AID502570	Inhibition of protein tyrosin kinase	2010	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18	Synthesis and biological activity of flavanone derivatives.
AID736060	Binding affinity to wild type Staphylococcus aureus alpha-hemolysin by fluorescence quenching method	2013	European journal of medicinal chemistry, Apr, Volume: 62	Molecular insight into the inhibition mechanism of cyrtominetin to α-hemolysin by molecular dynamics simulation.
AID502569	Antitumor activity against human KB cells	2010	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18	Synthesis and biological activity of flavanone derivatives.
AID502572	Cytoprotectant activity against H2O2-induced injury in HUVEC cells	2010	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18	Synthesis and biological activity of flavanone derivatives.
AID502571	Antivegetative activity against rat VSMC	2010	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18	Synthesis and biological activity of flavanone derivatives.
AID502567	Antitumor activity against human HL60 cells	2010	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18	Synthesis and biological activity of flavanone derivatives.
AID736059	Binding affinity to Staphylococcus aureus alpha-hemolysin I5A mutant by fluorescence quenching method	2013	European journal of medicinal chemistry, Apr, Volume: 62	Molecular insight into the inhibition mechanism of cyrtominetin to α-hemolysin by molecular dynamics simulation.
AID502566	Antitumor activity against human Bel7402 cells	2010	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18	Synthesis and biological activity of flavanone derivatives.
AID502568	Antitumor activity against human BGC823 cells	2010	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18	Synthesis and biological activity of flavanone derivatives.
AID736061	Inhibition of purified Staphylococcus aureus alpha-hemolysin-induced hemolysis of rabbit erythrocytes after 20 mins by spectrophotometry	2013	European journal of medicinal chemistry, Apr, Volume: 62	Molecular insight into the inhibition mechanism of cyrtominetin to α-hemolysin by molecular dynamics simulation.
AID736057	Inhibition of deoxycholate-induced wild type Staphylococcus aureus alpha-hemolysin oligomerization at 16 ug/ml by SDS-PAGE analysis	2013	European journal of medicinal chemistry, Apr, Volume: 62	Molecular insight into the inhibition mechanism of cyrtominetin to α-hemolysin by molecular dynamics simulation.
AID736056	Inhibition of deoxycholate-induced Staphylococcus aureus alpha-hemolysin I5A mutant oligomerization at 16 ug/ml by SDS-PAGE analysis	2013	European journal of medicinal chemistry, Apr, Volume: 62	Molecular insight into the inhibition mechanism of cyrtominetin to α-hemolysin by molecular dynamics simulation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (14.29)	18.7374
1990's	4 (57.14)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (28.57)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.75 (24.57)
Research Supply Index	2.08 (2.92)
Research Growth Index	4.83 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.75)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	1.98	1	0	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	1.98	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
tetrandrine tetrandrine: a bisbenzylisoquinoline that exhibits antifibrogenic activity	2.05	1	0	bisbenzylisoquinoline alkaloid; isoquinolines
(2S)-5,7-dihydroxy-6,8-dimethylflavanone (2S)-5,7-dihydroxy-6,8-dimethylflavanone : A dihydroxyflavanone that is (2S)-flavanone substituted by hydroxy groups at positions 5 and 7 and methyl groups at positions 6 and 8. Isolated from the buds of Cleistocalyx operculatus, it has been shown to exhibit inhibitory effects on the viral neuraminidases from two influenza viral strains, H1N1 and H9N2.	2.05	1	0	dihydroxyflavanone	EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; plant metabolite
n-formylmethionine leucyl-phenylalanine N-Formylmethionine Leucyl-Phenylalanine: A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated.. N-formyl-L-methionyl-L-leucyl-L-phenylalanine : A tripeptide composed of L-Met, L-Leu and L-Phe in a linear sequence with a formyl group at the amino terminus. It acts as a potent inducer of leucocyte chemotaxis and macrophage activator as well as a ligand for the FPR receptor.	1.98	1	0	tripeptide
leukotriene b4 Leukotriene B4: The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene B4 : A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway.	1.98	1	0	dihydroxy monocarboxylic acid; hydroxy polyunsaturated fatty acid; leukotriene; long-chain fatty acid	human metabolite; mouse metabolite; plant metabolite; vasoconstrictor agent
genistein [no description available]	2.05	1	0	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	1.98	1	0	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	1.98	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Atherogenesis [description not available]	0	2.05	1	0
Benign Neoplasms [description not available]	0	2.05	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	2.05	1	0
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	0	2.05	1	0
Extravascular Hemolysis [description not available]	0	2.08	1	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	0	2.08	1	0
Anesthesia A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.	0	1.98	1	0
Bronchial Hyperreactivity Tendency of the smooth muscle of the tracheobronchial tree to contract more intensely in response to a given stimulus than it does in the response seen in normal individuals. This condition is present in virtually all symptomatic patients with asthma. The most prominent manifestation of this smooth muscle contraction is a decrease in airway caliber that can be readily measured in the pulmonary function laboratory.	0	1.98	1	0